CRM vs JNJ: Which Is the Better Buy?
Side-by-side comparison of Salesforce, Inc. and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
Salesforce, Inc. · Technology
$236.42
+11.6% upside to fair value
Med Conviction
Grade B
High Quality
VS
Johnson & Johnson · Healthcare
$270.68
+5.7% upside to fair value
Med Conviction
Grade C
High Quality
QuantHub Verdict
CRM has more upside to fair value
(+11.6%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRM |
JNJ |
| Current Price |
$236.42 |
$270.68 |
| Fair Value Estimate |
$263.88 |
$286.05 |
| Upside to Fair Value |
+11.6%
|
+5.7%
|
| Market Cap |
$193.6B |
$652.3B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
14.4x
|
20.2x
|
| Price / Sales |
4.4x
|
6.7x
|
| Price / FCF |
12.8x
|
35.3x
|
| Revenue Growth YoY |
+10.8%
|
+6.6%
|
| Gross Margin |
77.3%
|
67.9%
|
| Operating Margin |
21.4%
|
26.8%
|
| Return on Equity |
20.2%
|
25.7%
|
| Dividend Yield |
0.73% |
1.95% |
| FCF Yield |
7.82%
|
2.83%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
Salesforce is the leading enterprise customer relationship management platform, spanning Sales, Service, Platform, Marketing, Commerce, Tableau, MuleSoft, and Slack under the Customer 360 umbrella, with 83,334 employees and a business that converts $53.65 of revenue per share into $18.48 of free cash flow per share. Business quality is high: TTM gross margin of 77.3%, TTM operating margin of 21.4…
Johnson & Johnson is a 141,700-employee healthcare holding company operating two segments, Innovative Medicine (immunology, oncology, neuroscience, infectious disease, cardiovascular and metabolism, pulmonary hypertension) and MedTech (interventional solutions, orthopaedics, surgery, vision), founded in 1887 and headquartered in New Brunswick, New Jersey. Business quality is high on fundamentals:…
Accumulation Zones
| Metric |
CRM |
JNJ |
| Zone Low |
$197.91 |
$214.54 |
| Zone High |
$224.30 |
$243.14 |
| In Buy Zone? |
No
|
No
|